The m6A reader protein YTHDC2 is a potential biomarker and associated with immune infiltration in head and neck squamous cell carcinoma

Yang Li¹,²*, Ji-Na Zheng¹*, En-Hao Wang⁴, Chan-Juan Gong¹, Keng-Fu Lan¹ and XiaoJun Ding¹,²

¹ Department of Stomatology, Zhongshan Hospital, Fudan University, Shanghai, China
² State Key Laboratory of Molecular Engineering of Polymers, Fudan University, Shanghai, China
³ Department of Dermatology, Zhongshan Hospital, Fudan University, Shanghai, China
⁴ Department of Otolaryngology, Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
* These authors contributed equally to this work.

ABSTRACT

Background. Increasing evidence has shown that N6-methyladenosine (m6A) RNA methylation regulators have important biological functions in human cancers. However, there are few studies on the value of m6A reader protein YTHDC2 in the diagnosis and tumor-infiltrating of head and neck squamous cell carcinoma (HNSCC). Therefore, it is important to understand the potential clinical value of YTHDC2 in the prognosis and immune infiltration of HNSCC.

Methods. In this study, gene expression profiles and the corresponding clinical information of 270 HNSCC patients were downloaded from the Gene Expression Omnibus (GEO) database. The gene co-expression network was established to verify whether YTHDC2 was related to the prognosis of HNSCC and verified again in the public database. The correlations between YTHDC2 and immune infiltration was investigated via Tumor Immune Estimation Resource (TIMER) and Gene Expression Profiling Interactive Analysis (GEPIA).

Results. The results showed that YTHDC2 appeared in the blue module related to survival time and survival state and had a close correlation with the prognosis and immune infiltration level of HNSCC in public database. Patients with low expression of YTHDC2 had poor overall survival (OS) and recurrence-free survival (RFS) than those with high expression. In addition, the expression of YTHDC2 was positively correlated with the level of CD4+ T cell subpopulations infiltration in HNSCC.

Conclusions. Through this study, we found that YTHDC2 is a tumor suppressor gene with high expression in normal tissues and low expression in tumor tissues. In addition, YTHDC2 is correlated with the immune infiltrating levels of B cells, CD8+ T cells, CD4+ T cells, neutrophils, and dendritic cells in HNSCC, which may become a potential marker for prognosis and immune infiltration of HNSCC.
INTRODUCTION

Head and neck squamous cell carcinoma (HNSCC) is one of the most common malignant tumors in the world (Ferlay et al., 2010). HNSCC mainly include neck tumors, nasopharyngeal tumors, oral and maxillofacial tumors (Leemans, Snijders & Brakenhoff, 2018). At present, studies have found that tobacco and alcohol are important factors in inducing HNSCC (Jethwa & Khariwala, 2017; Kawakita & Matsuo, 2017). The incidence of HNSCC is also relatively high in the world, which not only directly affects patients’ breathing, eating and language functions, but also causes rapid growth of neck lymph node metastasis with the help of abundant blood supply and lymphatic refluence (De Sousa et al., 2015). The main clinical treatment methods for HNSCC include surgery, radiotherapy and chemotherapy (Cramer et al., 2019).

N6-methyladenosine (m₆A) methylation is a methylation modification on RNA molecules, which was first discovered in 1974 (Dubin & Taylor, 1975). The m₆A methylation is a reversible dynamic RNA modification that may affect biological regulation, similar to DNA methylation and protein phosphorylation. Adenosine methylation in mRNA plays a regulatory role by changing mRNA function and affecting gene expression (Meyer & Jaffrey, 2014). The m₆A modification is mainly related to three types of proteases. The first is m₆A methyltransferase, whose coding genes are called “Writers”, including methyltransferase like 3 (METTL3), METTL14, METTL16, wilm’s tumor 1-associating protein (WATP). They form a complex that causes the m₆A methylated group to be written into the RNA (Cui et al., 2017). The second type of protein is m₆A demethylase, which encodes genes called “Erasers”. These proteins can remove the m₆A methylated group from RNA, thereby affecting tumor biological processes (Huang et al., 2015). The last group of proteins that bind to the m₆A methylation site to play specific biological functions, which encodes genes called “Readers”. They can recognize mRNA containing m₆A and regulate the expression of downstream genes accordingly (Meyer & Jaffrey, 2017). Although RNA m₆A modifications are shaped in a dynamic and reversible manner by the involvement of methyltransferases and demethylases, the proteins that preferentially identify m₆A-modified can bind to the methylated RNA and give it specific functions. The YT521-B homology (YTH) family with RNA-binding domains were the first “readers” to bind directly to the m₆A sites of RNA. Some scholars have found that YTH domain can selectively bind m₆A sites in RNA to give YTH domain proteins specific functions. Proteins modified by m₆A and containing the YTH domain can be identified as: YTH domain-containing 1-2 (YTHDC1-2) and YTH N6-methyladenosine RNA binding protein 1-3 (YTHDF1-3). The YTH family protein YTHDF1-3 and its nuclear members YTHDC1 and YTHDC2 can bind directly to RNA containing m₆A (Wang et al., 2014).

YTHDC2 can improve the efficiency of the translation and reduce the abundance of mRNA through its helicase and can improve the efficiency of HIF-1α mRNA translation (Tanabe et al., 2016), and can adjust the happening of the sperm (Hsu et al., 2017). Recent studies have shown that low expression of YTHDC2 was associated with poor prognosis and correlated with activation of apoptosis and ubiquitin-mediated proteolysis in HNSCC (Zhou et al., 2020). Besides, Zhao & Cui (2019) also found that two m6A methylation
“readers”—YTHDC2 and heterogeneous nuclear ribonucleoprotein C (HNRNPC) could construct a prognostic signature and predict the survival time in HNSCC patients.

This study investigated whether YTHDC2 was associated with the diagnosis and prognosis of HNSCC. We comprehensively analyzed the expression of YTHDC2 in HNSCC patients and its relationship with prognosis in the Gene Expression Omnibus (GEO) database and multiple public databases. In addition, we also investigated the association between the expression level of YTHDC2 and immune cell infiltration. This study found that YTHDC2 could act as an independent gene as a HNSCC prognostic marker, and provided a potential relationship between YTHDC2 and the interaction of tumor immune infiltration of HNSCC.

MATERIALS & METHODS
Validation of prognostic genes by weighted gene co-expression network analysis (WGCNA)
In order to validate YTHDC2 whether associated with the prognosis in HNSCC patients, the datasets of GSE65858 were downloaded from the GEO database. This database contained the gene expression of 270 HNSCC patients, as well as a series of corresponding clinical information (overall survival time, survival status, progression-free survival, age, smoking, tumor type, stage, TNM stage). We analyzed the top 25% of genes with the largest variance and used the “WGCNA” package of R 3.6.1 software (Zhao et al., 2010). Firstly, the scale-free network was constructed by the soft threshold $\beta$ of the appropriate adjacency matrix. With the expression matrix and the estimated optimal $\beta$ values, the co-expression matrix can be built directly. The similarity between genes was calculated according to the adjacency, and the system cluster tree among genes was obtained. According to the standard of hybrid dynamic shear tree, the minimum number of genes in each gene module was set as 30. After determining the gene modules, the characteristic vector value of each module was calculated in turn, and then cluster analysis was carried out to merge the modules close to each other into the new module (height = 0.25). Then, the correlation between the modules and traits was analyzed, and the module containing YTHDC2 were selected for further analysis. In addition, we obtained the gene significance (GS) and module membership (MM). Finally, we found that YTHDC2 was associated with prognosis, which was verified again in the public database.

Bio-informational analysis of YTHDC2 expression from public database
Oncolnc database
We used the survival data of HNSCC patients with different expression levels of YTHDC2 contained in Oncolnc database to establish kaplan-Meier survival curve, so as to study the influence of YTHDC2 expression in HNSCC on prognosis (Gao et al., 2018).

Kaplan–Meier plotter database
Kaplan–Meier plotter is a powerful public database that can assess the impact of thousands of genes on the survival for cancers. Sources for the database include GEO, the European
Genome-phenome Archive (EGA), and The Cancer Genome Atlas (TCGA) (Lánczky et al., 2016). Kaplan–Meier plotter was used to analyze the correlation between the expression of YTHDC2 and survival time in HNSCC. The 95% confidence interval of the hazard ratio (HR) and P values were calculated.

**TIMER database analysis**
TIMER database is a public online database, which can analyze the prognosis of cancer information as well as the different tumor immunity infiltration data (Li et al., 2017). We used TIMER database to analyze the expression of YTHDC2 in different types of cancer. In addition, we also analyzed the correlation between immune infiltration abundance of the CD8+ T cells, CD4+ T cells, B cells, neutrophils, macrophages, and dendritic cells with the expression of YTHDC2. In addition, we also make the correlation analysis between YTHDC2 and related genes and markers referenced in prior studies of multiple immune cells in TIMER (Siemers et al., 2017; Danaher et al., 2017; Mousset et al., 2019). Besides, we used TIMER2.0 version to analyzed the correlation between the immune infiltration and the expression of YTHDC2 (Li et al., 2020c). The outcome module of Timer 2.0 can explore the clinical correlation of tumor immune subsets and flexibly select covariables, which may be clinical factors or gene expression, to construct a corrected multivariate Cox proportional hazard models. By inputting immune cell types and gene YTHDC2, TIMER 2.0 will perform Cox regression analysis to create an independent Cox model. In addition, the immune infiltration estimations for users-provided expression profiles by multiple algorithms.

**Gene correlation analysis in GEPIA**
Gene expression Profiling Interactive Analysis (GEPIA) can be used to analyze the RNA expression data of different cancers and normal tissues from the TCGA database and the Genotype-Tissue Expression (GTEx) (Tang et al., 2017). Therefore, we used GEPIA to perform survival analysis of HNSCC and P < 0.05 was statistically significant.

**Gene alteration of YTHDC2 in HNSCC from cBioPortal**
We obtained YTHDC2 genetic change information in HNSCC by using cBioPortal (Gao et al., 2013). We draw the OncoPrint schematic diagram to reflect the various types of changes (missense mutation, truncating mutation, amplification, deep deletion, up-regulation and down-regulation of mRNA) of YTHDC2 in 279 HNSCC patients. Next, we constructed the Kaplan-Meier survival curve to evaluate the impact of YTHDC2 changes on HNSCC patients’ survival. The histogram showed the alteration frequency of YTHDC2 in HNSCC from different sources and tissues.

**Immunohistochemistry (IHC)**
We collected paraffin-embedded tissue blocks confirmed as HNSCC in our hospital for IHC analysis, and a total of 10 pairs of normal tissues and HNSCC tissues were stained. Firstly, paraffin sections were dewaxed, and the antigen retrieval was performed, and endogenous peroxidase activity was blocked with 0.3% hydrogen peroxide for 25 min at 37°C. Following antigen retrieval, the tissue sections were incubated with primary antibody
YTHDC2 (1: 500; EPR21820–EPR21849, AB220160; Abcam, Inc., Cambridge, MA, USA) at 4° C overnight. The next day, after washing with phosphate buffer saline (PBS) for the third time, then secondary antibody was added to incubate 50 min at room temperature. Then, we used diaminobenzidine (DAB) for staining, and hematoxylin was used to re-dye the nucleus.

RESULTS

Co-expression analysis by WGCNA

The WGCNA analysis can be used to explore the relationship between gene networks and related phenotypes by establishing co-expressed gene modules. Firstly, the data of 270 HNSCC patients were downloaded from the database GSE65858 (Fig. 1A) and the power of $\beta = 4$ was chose to construct a co-expression matrix (Figs. 1B and 1C). Finally, we obtained 17 gene co-expression modules. All the modules are represented by different colors, and the gray module showed the genes that cannot be categorized into any module (Fig. 1D). Figure 1E showed the blue module was closely related to the survival time ($P = 0.007$), survival status ($P = 0.05$), stage ($P = 3e-04$) and lymph node metastasis ($P = 0.009$) of HNSCC patients after the module combined with clinical features. Finally, we drew the scatter diagram of GS vs MM in the blue module. It can be seen here that YTHDC2 was not only highly correlated with its corresponding module, but also highly correlated with its corresponding traits (survival time, survival state) (Figs 1F and 1G).

The mRNA expression levels of YTHDC2 in different cancer types

To further evaluate the expression of YTHDC2 in human cancers, we used the RNA-seq data from multiple malignant tumors in TCGA database to detect their expression. Differential expression of YTHDC2 in all TCGA tumors and adjacent normal tissues was shown in Fig. 2. Compared with adjacent normal tissues, the expression of YTHDC2 in HNSCC was significantly decreased ($P < 0.001$).

Immunohistochemical analysis

We performed IHC analysis to confirm whether YTHDC2 was relatively low expressed in tumor tissues, and the result showed the protein expression of YTHDC2 in HNSCC tissue were down-regulated compared with normal tissues, which was consistent with the previous database (Figs. 3A–3D). Based on the above results, we found that YTHDC2 were expressed more highly in normal tissues than in HNSCC.

The prognostic significance of YTHDC2 expression in HNSCC

Figure 4A showed that HNSCC patients with higher YTHDC2 expression had a better prognosis than patients with lower YTHDC2 expression ($P = 0.0186$) from Oncolnc database. For further verification, we evaluated the prognostic value of YTHDC2 in HNSCC using Kaplan–Meier plotter database, and we found that low expression of YTHDC2 was also associated with poor overall survival (OS) and recurrence-free survival (RFS) (OS HR = 0.65, 95% CI [0.48–0.89], $P = 0.0065$; RFS HR = 2.57, 95% CI [1.21–5.48], $P = 0.011$) (Figs. 4B and 4C). The two databases show consistent results.
Figure 1  Construction of weighted gene co-expression network construction and identification of the hub module. (A) Clustering dendrogram of samples and the clinical traits of overall survival time, survival status, progression-free survival (pfs), age, smoking, tumor type, stage, TNM stage are displayed at the bottom. (B–C) The scale independence and the mean connectivity of the weighted gene co-expression network analysis (WGCNA) analysis of the head and neck squamous cell carcinoma (HNSCC). Testing the scale free topology when $\beta = 4$.  (D) Clustering dendrograms and modules identified by WGCNA. (E) Correlation between module eigengenes and clinical traits. The blue module containing YTHDC2 is selected. (F–G) The scatter diagram of gene significance (GS) vs module membership (MM) in the blue module with survival time and survival state of HNSCC. Gene YTHDC2 has been highlighted in red dots, the cutoff of blue module membership = 0.26, the cutoff of gene significance for survival state = 0.12, and the cutoff of gene significance for survival time = 0.05.

Full-size DOI: 10.7717/peerj.10385/fig-1
Low expression of YTHDC2 impacts the OS of HNSCC in patients with different clinicopathological factors

We used the Kaplan-Meier plotter database to study the relationship between the expression of YTHDC2 and different clinical characteristics of HNSCC patients. The results showed that low expression of YTHDC2 was associated with poor OS in male patients, grade 1 and grade 2 as well as low mutation burden ($P < 0.05$). In addition, low expression of YTHDC2 was correlated with worse OS in different cellular content (Basophils, B-cells, CD4+ memory cells, CD8+ T-cells, Eosinophils, Macrophages, Mesenchymal stem cells, Natural killer T-cells, Regulatory T-cells, Type 1 T-helper cells, Type 2 T-helper cells) of HNSCC patients (Table 1).

YTHDC2 correlated with immune infiltration level in HNSCC

Previously, we observed the blue module was closely related to lymph node metastasis ($P = 0.009$) of HNSCC patients (Fig. 1D). Thus, we investigated whether the expression of YTHDC2 was related to the immune infiltration level in HNSCC. We evaluated the correlation between the expression of YTHDC2 with immune infiltration levels in HNSCC from the TIMER. The results showed that the expression of YTHDC2 was significantly correlated with tumor purity ($r = −0.145$, $P = 1.29e−03$), B cell ($r = 0.098$, $P = 3.26e−02$), CD8+ T cells ($r = 0.191$, $P = 2.72e−05$), CD4+ T cells ($r = 0.21$, $P = 3.50e−06$), neutrophils ($r = 0.241$, $P = 9.46e−08$) and dendritic cells ($r = 0.216$, $P = 1.65e−06$) in HNSCC (Figs. 5A–5G). In addition, YTHDC2 expression has no significant correlations with the infiltrating levels of Macrophage in HNSCC. These findings strongly suggested that YTHDC2 expression played an important role in the immune infiltration of HNSCC, especially for CD4+ T cells and dendritic cells.
Correlation analysis between YTHDC2 expression and immune marker sets

In order to study the relationship between YTHDC2 and different immune infiltrated cells, we used TIMER and GEPIA database simultaneously to study the correlation between YTHDC2 expression level in normal tissues and HNSCC tissues and immune marker sets in different immune cells. We found that the expression level of YTHDC2 was correlated with the immunomarker sets of most of the different T cells in HNSCC after the purity correlation adjustment. Notably, we found that the expression level of most CD4+ T cell subpopulation marker sets was closely related to the expression of YTHDC2 in HNSCC (Table 2). Specifically, the results showed STAT1 of T-helper 1 (Th1) cells, STAT6 of T-helper 2 (Th2) cells, BCL6 of follicular helper T (Tfh) cells, STAT3 of T-helper 17 (Th17) cells, FOXP3, CCR8, CD25 (IL-2R α) and STAT5B of Tregs, IRF4 of T-helper 9 (Th9) cells, FOXO4, CD196 (CCR6) and CD194 (CCR4) of T-helper 22 (Th22) cells are significantly correlated with YTHDC2 expression in HNSCC (Correlation > 0.35, P < 0.0001; Fig. 6). To further verify the above results, we analyzed the correlation between YTHDC2 expression and the above markers of CD4+ T cell subsets in the GEPIA database. The results are similar to the above TIMER results (Table 3). Therefore, these results confirm the specific correlation between YTHDC2 and HNSCC immune infiltrated cells.
The prognostic signature built by the immune infiltration and the expression of YTHDC2

The infiltration level of CD4+ T cell subsets was divided into low and high levels and the covariate was selected as YTHDC2 expression. The hazard ratio and *P* value for Cox model were shown on the Kaplan–Meier survival curve plot. The results of Figs. 7A and
Table 1  Correlation of YTHDC2 mRNA expression and overall survival in HNSCC with different clinicopathological factors by Kaplan–Meier plotter. Values styled in bold style indicate $P < 0.05$.

| Clinicopathological characteristics | Overall survival |
|------------------------------------|------------------|
|                                    | $N$    | Hazard ratio  | $P$-value |
| **GENDER**                         |        |               |           |
| Female                             | 133    | 1.39 (0.85–2.29) | 0.1908 |
| Male                               | 366    | 0.46 (0.31–0.71)  | **0.00023** |
| **STAGE**                          |        |               |           |
| 1                                  | 25     | 0.19 (0.02–1.78)  | 0.1014 |
| 2                                  | 69     | 1.68 (0.57–4.94)  | 0.3403 |
| 3                                  | 78     | 0.63 (0.3–1.32)   | 0.2155 |
| 4                                  | 259    | 0.76 (0.54–1.08)  | 0.1266 |
| **GRADE**                          |        |               |           |
| 1                                  | 61     | 2.52 (1.03–6.17)  | **0.0371** |
| 2                                  | 298    | 0.61 (0.4–0.92)   | **0.0172** |
| 3                                  | 119    | 0.58 (0.3–1.13)   | 0.1066 |
| **MUTATION BURDEN**                |        |               |           |
| High                               | 251    | 0.66 (0.44–0.99)  | 0.1091 |
| Low                                | 243    | 0.58 (0.38–0.88)  | **0.0101** |
| **BASOPHILS**                      |        |               |           |
| Enriched                           | 243    | 0.64 (0.42–0.96)  | **0.0287** |
| Decreased                          | 254    | 0.65 (0.43–0.99)  | **0.0452** |
| **B-CELLS**                        |        |               |           |
| Enriched                           | 238    | 0.37 (0.21–0.65)  | **0.00035** |
| Decreased                          | 259    | 1.31 (0.8–1.61)   | 0.4894 |
| **CD4+ MEMORY CELLS**              |        |               |           |
| Enriched                           | 316    | 0.55 (0.35–0.85)  | **0.0146** |
| Decreased                          | 181    | 0.54 (0.33–0.89)  | **0.0146** |
| **CD8+ T-CELLS**                   |        |               |           |
| Enriched                           | 305    | 0.7 (0.49–1)      | **0.0489** |
| Decreased                          | 192    | 1.32 (0.86–2.01)  | 0.1973 |
| **EOSINOPHILS**                    |        |               |           |
| Enriched                           | 215    | 0.64 (0.42–0.96)  | **0.0315** |
| Decreased                          | 282    | 0.62 (0.4–0.95)   | **0.0259** |
| **MACROPHAGES**                    |        |               |           |
| Enriched                           | 205    | 0.6 (0.38–0.96)   | **0.0302** |
| Decreased                          | 292    | 0.66 (0.46–0.95)  | **0.0234** |
| **MENSENYMAL STEM CELLS**          |        |               |           |
| Enriched                           | 313    | 0.73 (0.52–1.03)  | 0.0723 |
| Decreased                          | 184    | 0.52 (0.33–0.8)   | **0.0029** |
| **NATURAL KILLER T-CELLS**         |        |               |           |
| Enriched                           | 129    | 0.66 (0.36–1.22)  | 0.1788 |
| Decreased                          | 368    | 0.69 (0.5–0.96)   | **0.0258** |

(continued on next page)
Table 1 (continued)

| Clinicopathological characteristics | Overall survival |
|-------------------------------------|------------------|
|                                     | N                | Hazard ratio | P-value   |
| REGULATORY T-CELLS                  |                  |              |           |
| Enriched                            | 322              | 0.68 (0.49–0.96) | 0.025     |
| Decreased                           | 175              | 0.63 (0.38–1.06) | 0.0775    |
| TH1 CELLS                           |                  |              |           |
| Enriched                            | 381              | 0.57 (0.39–0.82) | 0.002     |
| Decreased                           | 116              | 1.31 (0.73–2.38) | 0.3635    |
| TH2 CELLS                           |                  |              |           |
| Enriched                            | 473              | 0.65 (0.47–0.89) | 0.0064    |
| Decreased                           | 24               | 0.23 (0.04–1.48) | 0.0967    |

Figure 5 Correlation of YTHDC2 expression with immune infiltration level in head and neck squamous cell carcinoma (HNSCC). (A) Tumor purity (B) B cell (C) CD8+ T cells (D) CD4+ T cells (E) Macrophages (F) Neutrophils (G) Dendritic cells.

7D showed that high expression of YTHDC2 with high immune infiltration of Tfh cells or CD4+ native T cells have better prognosis than low expression of YTHDC2 with low immune infiltration of Tfh cells or CD4+ native T cells. However, the results of Figs. 7B and 7C showed that low YTHDC2 expression with low immune infiltration of CD4+ T cells or CD4+ native T cells have better prognosis than high expression of YTHDC2 with high immune infiltration of CD4+ T cells or CD4+ native T cells. However, it is not difficult to see that YTHDC2 with high expression level has a better prognosis than YTHDC2 with low expression level. Secondly, different CD4+ T cell subsets may have different effects on the prognosis of HNSCC.

Gene alteration of YTHDC2 in HNSCC from cBioPortal
The oncoprint schematic diagram showed gene alteration of YTHDC2 occurred in 37 of all the 279 sequenced cases (13%), including 3 cases of mutation, 1 cases of amplification, 1 case of deep deletion, 9 cases of mRNA up-regulation and 20 cases of mRNA down-regulation (Fig. 8A). However, the overall survival curve showed that there was no significant correlation between alteration of YTHDC2 and the overall survival of HNSCC patients (Fig. 8B). The statistical results of the frequency of gene alteration showed that YTHDC2 had a certain possibility of mutation (Fig. 8C).
| Description       | Gene markers     | HNSCC   |
|-------------------|------------------|---------|
|                   |                  | None    | Purity |
|                   |                  | Cor     | P      | Cor    | P      |
| CD8+ T cell       | CD8A             | 0.349   | ***    | 0.352  | ***    |
|                   | CD8B             | 0.262   | ***    | 0.253  | ***    |
|                   | CD3D             | 0.236   | ***    | 0.228  | ***    |
| T cell (general)  | CD3E             | 0.334   | ***    | 0.337  | ***    |
|                   | CD2              | 0.323   | ***    | 0.319  | ***    |
| B cell            | CD19             | 0.285   | ***    | 0.287  | ***    |
|                   | CD79A            | 0.309   | ***    | 0.314  | ***    |
| Monocyte          | CD86             | 0.244   | ***    | 0.244  | ***    |
|                   | CSF1R            | 0.299   | ***    | 0.301  | ***    |
|                   | CD79A            | 0.309   | ***    | 0.314  | ***    |
| TAM               | CD68             | 0.090   | 0.04   | 0.086  | 0.058  |
|                   | IL10             | 0.265   | ***    | 0.266  | ***    |
| M1 Macrophage     | NOS2             | 0.337   | ***    | 0.331  | ***    |
|                   | IRF5             | 0.258   | ***    | 0.263  | ***    |
|                   | PTGS2            | 0.130   | *      | 0.129  | *      |
| M2 Macrophage     | CD163            | 0.276   | ***    | 0.284  | ***    |
|                   | VSIG4            | 0.196   | ***    | 0.196  | ***    |
|                   | MS4A4A           | 0.215   | ***    | 0.213  | ***    |
| Neutrophils       | CEACAM8          | 0.046   | 0.293  | 0.045  | 0.321  |
|                   | ITGAM            | 0.319   | ***    | 0.317  | ***    |
|                   | CCR7             | 0.320   | ***    | 0.314  | ***    |
|                   | KIR2DL1          | 0.145   | **     | 0.161  | **     |
|                   | KIR2DL3          | 0.247   | ***    | 0.243  | ***    |
|                   | KIR2DL4          | 0.275   | ***    | 0.298  | ***    |
|                   | KIR3DL1          | 0.275   | ***    | 0.289  | ***    |
|                   | KIR3DL2          | 0.277   | ***    | 0.276  | ***    |
|                   | KIR3DL3          | 0.134   | *      | 0.120  | *      |
|                   | KIR2DS4          | 0.132   | *      | 0.135  | *      |
| Natural killer cell| HLA-DPB1        | 0.238   | ***    | 0.236  | ***    |
|                   | HLA-DQB1        | 0.222   | ***    | 0.207  | ***    |
|                   | HLA-DRA         | 0.322   | ***    | 0.324  | ***    |
| Dendritic cell    | HLA-DPA1        | 0.342   | ***    | 0.340  | ***    |
|                   | CD1C            | 0.254   | ***    | 0.242  | ***    |
|                   | NRP1            | 0.300   | ***    | 0.305  | ***    |
|                   | ITGAX           | 0.293   | ***    | 0.308  | ***    |

(continued on next page)
Table 2 (continued)

| Description | Gene markers | HNSCC | None | P | Purity | Cor | P |
|-------------|--------------|-------|------|---|--------|-----|---|
| TBX21       | 0.300        | ***   | 0.300 | *** |
| STAT4       | 0.290        | ***   | 0.285 | *** |
| STAT1       | 0.350        | ***   | 0.354 | *** |
| IFN-γ (IFNG)| 0.276        | ***   | 0.280 | *** |
| TNF-α (TNF)| 0.147        | **    | 0.156 | **  |
| GATA3       | 0.190        | ***   | 0.182 | *** |
| TB1         | 0.460        | ***   | 0.461 | *** |
| STAT6       | 0.320        | ***   | 0.315 | *** |
| IL13        | 0.199        | ***   | 0.192 | *** |
| BCL6        | 0.363        | ***   | 0.369 | *** |
| Th17        | 0.352        | ***   | 0.335 | *** |
| IL17A       | 0.277        | ***   | 0.268 | *** |
| FOXP3       | 0.422        | ***   | 0.431 | *** |
| CCR8        | 0.519        | ***   | 0.521 | *** |
| Treg        | 0.344        | ***   | 0.344 | *** |
| CD4         | 0.340        | ***   | 0.372 | *** |
| CD25 (IL-2Rα)| 0.408      | ***   | 0.407 | *** |
| IRF4        | 0.392        | ***   | 0.399 | *** |
| Th9         | 0.234        | ***   | 0.238 | *** |
| IL22        | 0.167        | **    | 0.155 | **  |
| FOXP4       | 0.425        | ***   | 0.422 | *** |
| Th22        | 0.329        | ***   | 0.329 | *** |
| AHR         | 0.401        | ***   | 0.404 | *** |
| CD196 (CCR6)| 0.498        | ***   | 0.496 | *** |

Notes.

*P < 0.05.

**P < 0.01.

***P < 0.001.

DISCUSSION

Modification of m6A is a complex regulatory network and participates in various stages of the RNA life cycle, from RNA processing, nuclear output, translation regulation to RNA degradation, indicating that m6A has multiple functions related to RNA metabolism. Recent studies have shown that m6A methylation is closely related to the development and progression of tumors (Li et al., 2020). The evolutionarily conserved YTH domain contained in the YTH protein family selectively recognizes m6A. YTHDC2 is located on human chromosome 5 with a length of 81kb. The relative molecular weight of YTHDC2 protein is 160kD, containing 1430 amino acid sequences. Like other proteins in the YTH family, YTHDC2 contains a YTH domain at the C end, which is formed by six-stranded β-sheet and three α-helices with positively
Figure 6  Scatterplots of correlations between YTHDC2 expression and gene markers of CD4+ T cells subsets. (A) Follicular helper T (Tfh) cells (B) T-helper 9 (Th9) cells (C) T-helper 17 (Th17) cells (D) T-helper 1 (Th1) cells (E) T-helper 2 (Th2) cells (F) Tregs (G) T-helper 22 (Th22) cells.

charged surface hydrophobic pockets, mediating binding to m6A (Theler et al., 2014; Xu et al., 2015). In addition, YTHDC2 differs from other YTH family proteins in that it has its own unique domain. Its RNA binding domain characterized R3H domain is involved in the binding of YTHDC2 to intracellular RNA, and plays an auxiliary role in the YTH domain. The Helicase domain of YTHDC2 has ATP-dependent RNA Helicase function, in which the ankyrin repeat (ANK) mediates the interaction with 5′-3′ exonuclease XRN1, suggesting that YTHDC2 may play a role in regulating mRNA stability (Kretschmer et al., 2018). However, the function of DUF1065 domain of YTHDC2 is not yet clear and needs further study. As the final member of the YTH protein family, the biological function of YTHDC2 is still not fully understood. Kretschmer et al. (2018) showed that YTHDC2 is mainly enriched in the perinuclear region and can bind to ribosomes and act on small ribosomal subunits to improve translation efficiency. Wojtas et al. (2017) found that YTHDC2 has the activity of 3′→5′ RNA helicase, which can regulate the transcription level of m6A-modified germline, so as to maintain the gene expression program of meiosis process. Other studies have shown that YTHDC2 may be associated with autism (Liu et al., 2016), and may also be a potential susceptibility gene for pancreatic cancer (Fanale et al., 2014). It also plays an important role in the occurrence and development of liver cancer (Tanabe et al., 2014), but the relationship between YTHDC2 and HNSCC has been rarely studied.

Head and neck tumors are the sixth most common type of malignancy in the world, with HNSCC accounting for 90%. There are more than 550,000 new cases and 380,000 deaths worldwide each year. According to the TNM stage of the tumor, the current treatment methods of HNSCC mainly include surgical treatment, radiotherapy and chemotherapy, but the treatment effect is still not satisfactory.
Table 3  Correlation analysis between YTHDC2 and related genes and markers of CD4+ T cells subsets in GEPIA.

| Description | Gene markers | HNSCC |
|-------------|-------------|-------|
|             | Tumor       | Normal|
|             | R        | P  | R    | P  |
| Th1         |           |     |      |     |
| TBX21       | 0.28      | ***| 0.14 | 0.37|
| STAT4       | 0.27      | ***| 0.25 | 0.11|
| STAT1       | 0.36      | ***| 0.48 | ** |
| IFN-γ (IFNG)| 0.25      | ***| 0.11 | 0.47|
| TNF-α (TNF)| 0.16      | ** | 0.29 | 0.055|
| GATA3       | 0.2       | ***| −0.11| 0.47|
| Th2         |           |     |      |     |
| STAT6       | 0.5       | ***| 0.87 | ***|
| STAT5A      | 0.33      | ***| 0.085| 0.58|
| IL13        | 0.21      | ***| −0.044| 0.78|
| BCL6        | 0.41      | ***| 0.4  | *  |
| Th           |           |     |      |     |
| IL21        | 0.35      | ***| 0.24 | 0.12|
| STAT3       | 0.59      | ***| 0.64 | ***|
| Th17        |           |     |      |     |
| IL17A       | 0.26      | ***| 0.41 | *  |
| FOXP3       | 0.35      | ***| 0.3  | 0.045|
| CCR8        | 0.49      | ***| 0.29 | 0.052|
| Treg        |           |     |      |     |
| CD4         | 0.33      | ***| 0.18 | 0.25|
| CD25 (IL2RA)| 0.32      | ***| 0.16 | 0.29|
| STAT5B      | 0.42      | ***| 0.091| 0.55|
| Th9         |           |     |      |     |
| IRE4        | 0.37      | ***| 0.051| 0.74|
| PU.1 (SPI1)| 0.2       | ***| 0.02 | 0.9 |
| IL22        | 0.2       | ** | 0.47 | *  |
| Th22        |           |     |      |     |
| FOXO4       | 0.45      | ***| 0.21 | 0.17|
| AHR         | 0.35      | ***| 0.65 | ***|
| CD196 (CCR6)| 0.34      | ***| 0.33 | 0.027|
| CD194 (CCR4)| 0.45      | ***| 0.29 | 0.054|

Notes.
*P < 0.05.
**P < 0.01.
***P < 0.001.

In this study, to investigate the role of YTHDC2 in HNSCC, gene co-expression network was established to verify whether YTHDC2 was related to the prognosis of HNSCC. We found that YTHDC2 appeared in the blue module related to survival time and survival state. Later, we verified it again in the public database, and we found that there was a close correlation between YTHDC2 and the prognosis of HNSCC. Through this study, we found that YTHDC2 is a tumor suppressor gene with high expression in normal tissues and low expression in tumor tissues through IHC analysis. In addition, the expression of YTHDC2 was significantly correlated with immune infiltration level and had a high mutation frequency. Our results demonstrated that there was a positive relationships between YTHDC2 expression level and infiltration level of CD4+ T cell subsets in HNSCC. However there are few articles reported on the correlation between YTHDC2 expression
level and infiltration level of CD4+ T cell subsets in HNSCC. At present, studies have shown that m6A modification plays an important role in the diversity and complexity of tumor microenvironment (Zhang et al., 2020). He et al. (2020) revealed that high RNA methylation modification group was associated with significantly higher numbers of tumor-infiltrating CD8+ T cells, Th cells and activated NK cells, but lower expressions of PD-L1, PD-L2, TIM3, and CCR4 than low RNA methylation modification group in breast cancer patients. Li et al. (2020a) found low WTAP expression was associated with a high T cell-related immune response, and lymphocyte infiltration in patients with low WTAP expression was well correlated with the prognosis of gastric cancer. Besides, current study has found \( \alpha \)-ketoglutarate-dependent dioxygenase alkB homolog 5 (ALKBH5) can...
modulate the composition of tumor-infiltrating Tregs. The mutation and expression status of ALKBH5 correlate with their response to immunotherapy in melanoma patients (Li et al., 2020b). In this study, we found STAT1 of Th1 cells, STAT6 of Th2 cells, BCL6 of Tfh cells, STAT3 of Th17 cells, FOXP3, CCR8, CD25 (IL-2R) and STAT3 of Th17 cells, FOXP3, CCR8, CD25 (IL-2R) and STAT5B of Tregs, IRF4 of Th9 cells, FOXO4,CD196 (CCR6) and CD194 (CCR4) of Th22 cells are significantly correlated with YTHDC2 expression in HNSCC. Further experiments are needed to prove the correlation between YTHDC2 and CD4+ T cell subsets and the specific mechanism.

**CONCLUSIONS**

In conclusion, we found that m6A methylation regulator YTHDC2 may become a potential marker for molecular diagnosis and prognosis of HNSCC through this study, and will also provide a new target for the development of clinical molecular targeted therapy drugs. In addition, the expression of YTHDC2 was positively correlated with infiltrating levels of CD4+ T cells subsets in HNSCC. However, the specific mechanism of YTHDC2 acting on HNSCC needs further exploration.

**Abbreviations**
ALKBH5  \( \alpha \)-ketoglutarate-dependent dioxygenase alkB homolog 5
ANK  ankyrin repeat
DAB  diaminobenzidine
DCs  dendritic cells
EGA  European Genome-phenome Archive
GEO  Gene Expression Omnibus
GEPIA  Gene expression Profiling Interactive Analysis
GS  gene significance
GTEx  Genotype-Tissue Expression
HNRNPC  heterogeneous nuclear ribonucleoprotein C
HNSCC  head and neck squamous cell carcinoma
HR  hazard ratio
IHC  Immunohistochemistry
m6A  N6-methyladenosine
METTL3  methyltransferase like 3
MM  membership module
NK  natural killer
PBS  phosphate buffer saline
PFS  progression-free survival
RFS  recurrence-free survival
TCGA  The Cancer Genome Atlas
Th1  T-helper 1
Th2  T-helper 2
Th9  T-helper 9
Th17  T-helper 17
Th22  T-helper 22
WATP  wilm’s tumor 1-associating protein
WGCNA  weighted gene co-expression network analysis
Tfh  follicular helper T
YTH  YT521-B homology
YTHDC1-2  YTH domain-containing 1-2
YTHDF1-3  YTH N6-methyladenosine RNA binding protein 1-3

**ADDITONAL INFORMATION AND DECLARATIONS**

**Funding**
The authors received no funding for this work.

**Competing Interests**
The authors declare there are no competing interests.
Author Contributions

• Yang Li, Ji-Na Zheng, En-Hao Wang and XiaoJun Ding conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the paper, and approved the final draft.
• Chan-Juan Gong analyzed the data, authored or reviewed drafts of the paper, and approved the final draft.
• Keng-Fu Lan analyzed the data, prepared figures and/or tables, and approved the final draft.

Data Availability
The following information was supplied regarding data availability:
The data is available at NCBI GEO: GSE65858 and at the Head and Neck Squamous Cell Carcinoma (TCGA, Nature 2015). The original files of other datasets are available in the Supplemental Files.

Supplemental Information
Supplemental information for this article can be found online at http://dx.doi.org/10.7717/peerj.10385#supplemental-information.

REFERENCES

Cramer JD, Burtness B, Le QT, Ferris RL. 2019. The changing therapeutic landscape of head and neck cancer. Nature Reviews Clinical Oncology 16:669–683.

Cui Q, Shi H, Ye P, Li L, Qu Q, Sun G, Sun G, Lu Z, Huang Y, Yang CG, Riggs AD, He C, Shi YH. 2017. m(6)A RNA methylation regulates the self-renewal and tumorigenesis of glioblastoma stem cells. Cell Reports 18:2622–2634.

Danaher P, Warren S, Dennis L, D’Amico L, White A, Disis ML, Geller MA, Odunsi K, Beechem J, Fling SP. 2017. Gene expression markers of Tumor Infiltrating Leukocytes. Journal for ImmunoTherapy of Cancer 5:18 DOI 10.1186/s40425-017-0215-8.

De Sousa EA, Lourenco SV, De Moraes FP, Vartanian JG, Goncalves-Filho J, Kowalski LP, Soares FA, Coutinho-Camillo CM. 2015. Head and neck squamous cell carcinoma lymphatic spread and survival: relevance of vascular endothelial growth factor family for tumor evaluation. Head and Neck 37:1410–1416 DOI 10.1002/hed.23765.

Dubin DT, Taylor RH. 1975. The methylation state of poly A-containing messenger RNA from cultured hamster cells. Nucleic Acids Research 2:1653–1668.

Fanale D, Iovanna JL, Calvo EL, Berthezene P, Belleau P, Dagorn JC, Bronte G, Cicero G, Bazan V, Rolfo C, Santini D, Russo A. 2014. Germline copy number variation in the YTHDC2 gene: does it have a role in finding a novel potential molecular target involved in pancreatic adenocarcinoma susceptibility? Expert Opinion on Therapeutic Targets 18:841–850 DOI 10.1517/14728222.2014.920324.

Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. 2010. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer 127:2893–2917 DOI 10.1002/ijc.25516.
Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C, Schultz N. 2013. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Science Signaling 6:pl1 DOI 10.1126/scisignal.2004088.

Gao X, Chen Y, Chen M, Wang S, Wen X, Zhang S. 2018. Identification of key candidate genes and biological pathways in bladder cancer. Peerj 6:e6036 DOI 10.7717/peerj.6036.

He X, Tan L, Ni J, Shen G. 2020. Expression pattern of m(6)A regulators is significantly correlated with malignancy and antitumor immune response of breast cancer. Cancer Gene Therapy DOI 10.1038/s41417-020-00208-1.

Hsu PJ, Zhu Y, Ma H, Guo Y, Shi X, Liu Y, Qi M, Lu Z, Shi H, Wang J, Cheng Y, Luo G, Dai Q, Liu M, Guo X, Sha J, Shen B, He C. 2017. Ythdc2 is an N(6)-methyladenosine binding protein that regulates mammalian spermatogenesis. Cell Research 27:1115–1127 DOI 10.1038/cr.2017.99.

Huang Y, Yan J, Li Q, Li J, Gong S, Zhou H, Gan J, Jiang H, Jia GF, Luo C, Yang CG. 2015. Meclofenamic acid selectively inhibits FTO demethylation of m6A over ALKBH5. Nucleic Acids Research 43:373–384 DOI 10.1093/nar/gku1276.

Jethwa AR, Khariwala SS. 2017. Tobacco-related carcinogenesis in head and neck cancer. Cancer and Metastasis Reviews 36:411–423 DOI 10.1007/s10555-017-9689-6.

Kawakita D, Matsuo K. 2017. Alcohol and head and neck cancer. Cancer and Metastasis Reviews 36:425–434 DOI 10.1007/s10555-017-9690-0.

Kretschmer J, Rao H, Hackert P, Sloan KE, Hobartner C, Bohnsack MT. 2018. The m(6)A reader protein YTHDC2 interacts with the small ribosomal subunit and the 5′-3′ exoribonuclease XRN1. Rna 24:1339–1350 DOI 10.1038/nrc.2018.11.

Lánczky A, Á Nagy, Bottai G, Munkácsy G, Szabó A, Santarpia L, Győrffy B. 2016. miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients. Breast Cancer Research and Treatment 160:439–446 DOI 10.1007/s10549-016-4013-7.

Leemans CR, Snijders PJF, Brakenhoff RH. 2018. The molecular landscape of head and neck cancer. Nature Reviews Cancer 18:269–282.

Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, Li B, Liu XS. 2017. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Research 77:e108–e110 DOI 10.1158/0008-5472.Can-17-0307.

Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, Li B, Liu XS. 2020c. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Research 48:W509–W514 DOI 10.1093/nar/gkaa407.

Li N, Kang Y, Wang L, Huff S, Tang R, Hui H, Agrawal K, Gonzalez GM, Wang Y, Patel SP, Rana TM. 2020b. ALKBH5 regulates anti-PD-1 therapy response by modulating lactate and suppressive immune cell accumulation in tumor microenvironment. Proceedings of the National Academy of Sciences of the United States of America 117:20159–20170 DOI 10.1073/pnas.1918986117.

Li H, Su Q, Li B, Lan L, Wang C, Li W, Wang G, Chen W, He Y, Zhang C. 2020a. High expression of WTAP leads to poor prognosis of gastric cancer by influencing
tumour-associated T lymphocyte infiltration. *J Cell Mol Med* 24:4452–4465 DOI 10.1111/jcmm.15104.

Liu X, Shimada T, Otowa T, Wu YY, Kawamura Y, Tochigi M, Iwata Y, Umekage T, Toyota T, Maekawa M, Iwayama Y, Suzuki K, Kakiuchi C, Kuwabara H, Kano Y, Nishida H, Sugiyama T, Kato N, Chen CH, Mori N, Yamada K, Yoshikawa T, Kasai K, Tokunaga K, Sasaki T, Gau SS. 2016. Genome-wide association study of autism spectrum disorder in the east Asian populations. *Autism Research* 9:340–349 DOI 10.1002/aur.1536.

Meyer KD, Jaffrey SR. 2014. The dynamic epitranscriptome: N6-methyladenosine and gene expression control. *Nature Reviews Molecular Cell Biology* 15:313–326 DOI 10.1146/annurev-cellbio-100616-060758.

Meyer KD, Jaffrey SR. 2017. Rethinking m(6)A readers, writers, and erasers. *Annual Review of Cell and Developmental Biology* 33:319–342.

Mousset CM, Hobo W, Woestenenk R, Preijers F, Dolstra H, Van der Waart AB. 2019. Comprehensive phenotyping of T cells using flow cytometry. *Cytometry A* 95:647–654 DOI 10.1002/cyto.a.23724.

Siemers NO, Holloway JL, Chang H, Chasalow SD, Ross-MacDonald PB, Voliva CF, Szustakowski JD. 2017. Genome-wide association analysis identifies genetic correlates of immune infiltrates in solid tumors. *PLOS ONE* 12:e0179726 DOI 10.1371/journal.pone.0179726.

Tanabe A, Konno J, Tanikawa K, Sahara H. 2014. Transcriptional machinery of TNF-α-inducible YTH domain containing 2 (YTHDC2) gene. *Gene* 535:24–32 DOI 10.1016/j.gene.2013.11.005.

Tanabe A, Tanikawa K, Tsunetomi M, Takai K, Ikeda H, Konno J, Torigeo T, Maeda H, Kutomi G, Okita K, Mori M, Sahara H. 2016. RNA helicase YTHDC2 promotes cancer metastasis via the enhancement of the efficiency by which HIF-1alpha mRNA is translated. *Cancer Letters* 376:34–42 DOI 10.1016/j.canlet.2016.02.022.

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. 2017. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. *Nucleic Acids Research* 45:W98–W102 DOI 10.1093/nar/gkx247.

Theler D, Dominguez C, Blatter M, Boudet J, Allain FH. 2014. Solution structure of the YTH domain in complex with N6-methyladenosine RNA: a reader of methylated RNA. *Nucleic Acids Research* 42:13911–13919 DOI 10.1093/nar/gku1116.

Vu LP, Pickering BF, Cheng Y, Zaccara S, Nguyen D, Minuesa G, Chou T, Chow A, Saletore Y, MacKay M, Schulman J, Famulare C, Patel M, Klimek VM, Garrett-Bakelman FE, Melnick A, Carroll M, Mason CE, Jaffrey SR, Kharas MG. 2017. The N(6)-methyladenosine (m(6)A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells. *Nature Medicine* 23:1369–1376.

Wang X, Lu Z, Gomez A, Hon GC, Yue Y, Han D, Fu Y, Parisien M, Dai Q, Jia G, Ren B, Pan T, He C. 2014. N6-methyladenosine-dependent regulation of messenger RNA stability. *Nature* 505:117–120.
Weng H, Huang H, Wu H, Qin X, Zhao BS, Dong L, Shi H, Skibbe J, Shen C, Hu C, Sheng Y, Wang Y, Wunderlich M, Zhang B, Dore LC, Su R, Deng X, Ferchen K, Li C, Sun M, Lu Z, Jiang X, Marcucci G, Mulloy JC, Yang J, Qian Z, Wei M, He C, Chen J. 2018. METTL14 inhibits hematopoietic stem/progenitor differentiation and promotes leukemogenesis via mRNA m(6)A modification. *Cell Stem Cell* 22:191–205.

Wojtas MN, Pandey RR, Mendel M, Homolka D, Sachidanandam R, Pillai RS. 2017. Regulation of m(6)A Transcripts by the 3′→5′ RNA Helicase YTHDC2 Is essential for a successful meiotic program in the mammalian germline. *Molecular Cell* 68:374–387 DOI 10.1016/j.molcel.2017.09.021.

Xu C, Wang X, Liu K, Roundtree IA, Tempel W, Li Y, Lu Z, He C, Min J. 2015. Corrigendum: structural basis for selective binding of m(6)A RNA by the YTHDC1 YTH domain. *Nature Chemical Biology* 11:815 DOI 10.1038/nchembio1015-815c.

Zhang C, Samanta D, Lu H, Bullen JW, Zhang H, Chen I, He X, Semenza GL. 2016. Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated m(6)A-demethylation of NANOG mRNA. *Proceedings of the National Academy of Sciences of the United States of America* 113:E2047–E2056.

Zhao X, Cui L. 2019. Development and validation of a m(6)A RNA methylation regulators-based signature for predicting the prognosis of head and neck squamous cell carcinoma. *American Journal of Cancer Research* 9:2156–2169.

Zhang B, Wu Q, Li B, Wang D, Wang L, Zhou YL. 2020. m(6)A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in gastric cancer. *Molecular Cancer* 19:53 DOI 10.1186/s12943-020-01170-0.

Zhao W, Langfelder P, Fuller T, Dong J, Li A, Hovarth S. 2010. Weighted gene coexpression network analysis: state of the art. *Journal of Biopharmaceutical Statistics* 20:281–300 DOI 10.1080/10543400903572753.

Zhou X, Han J, Zhen X, Liu Y, Cui Z, Yue Z, Ding L, Xu S. 2020. Analysis of genetic alteration signatures and prognostic values of m6A regulatory genes in head and neck squamous cell carcinoma. *Frontiers in Oncology* 10:718 DOI 10.3389/fonc.2020.00718.